Current and Emerging Pharmacotherapies for Primary CNS Lymphoma
Open Access
- 1 January 2012
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 6, 219-31
Abstract
Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin's lymphoma (NHL) primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose methotrexate (HD-MTX) based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent studies have focused on using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar treatment rates and survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low incidence of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerging treatment options in patients with PCNSL.Keywords
This publication has 89 references indexed in Scilit:
- Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)Neuro-Oncology, 2011
- High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphomaLeukemia & Lymphoma, 2011
- Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine CombinationThe Oncologist, 2011
- High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaNeuro-Oncology, 2010
- Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trialBritish Journal of Cancer, 2010
- Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical CourseJournal of Clinical Oncology, 2008
- Pathway analysis of primary central nervous system lymphomaBlood, 2008
- High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinionsLeukemia & Lymphoma, 2008
- Temozolomide as salvage treatment in primary brain lymphomasBritish Journal of Cancer, 2007